SNX-2112 inhibits in vitro cell proliferation in hematologic malignancies
| Hematologic malignancy . | IC50, nM . | |
|---|---|---|
| SNX-2112 . | 17-AAG . | |
| Kasumi-1 (c-kit; AML) | 0.9 ± 0.3 | 305 ± 113 |
| IM9 (LCL) | 3 ± 1 | 1533 ± 34 |
| ARH77 (LCL) | 2 ± 1 | 1059 ± 206 |
| MCCAR (LCL) | 0.9 ± 0.4 | 210 ± 79 |
| HS SULTAN (LCL) | 9 ± 4 | 2036 ± 53 |
| K562 (erythroleukemia) | 5 ± 0.8 | 128 ± 81 |
| Hematologic malignancy . | IC50, nM . | |
|---|---|---|
| SNX-2112 . | 17-AAG . | |
| Kasumi-1 (c-kit; AML) | 0.9 ± 0.3 | 305 ± 113 |
| IM9 (LCL) | 3 ± 1 | 1533 ± 34 |
| ARH77 (LCL) | 2 ± 1 | 1059 ± 206 |
| MCCAR (LCL) | 0.9 ± 0.4 | 210 ± 79 |
| HS SULTAN (LCL) | 9 ± 4 | 2036 ± 53 |
| K562 (erythroleukemia) | 5 ± 0.8 | 128 ± 81 |
Various cell lines of hematologic malignancies were cultured with SNX-2112 or 17-AAG for 72 hours, and cell growth was evaluated by CellTiter-Glo luminescent cell viability assay. Values shown are means plus or minus SD of quadruplicate determinations. LCL indicates lymphoblastoid cell lines.